SAN FRANCISCO (Reuters) - The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

A young local startup offering virtual appointments for patients at risk for dementia and cognitive decline is getting ready ...

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

Invesco S&P 500 Pure Value ETF offers low valuations, but underperforms peers due to high volatility and expenses. Read what ...

Cerebral, the fully comprehensive online mental health care provider, is proud to announce their new partnership with the San ...

The Cigna Group (CI) is a global health services company worth a market cap of $79.2 billion. The Bloomfield, ...

Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...

Medicare Advantage (MA) insurers Alignment Healthcare and Clover Health both reported increased membership growth ahead of ...

Self-funded Pennsylvania-based health plan Imagine360 is buying Ardent Health’s third-party administrator (TPA) HealthFirst, ...